Here we propose, for the first time, that a BChE mutant with significantly improved catalytic activity against ghrelin could be used as an exogenous enzyme to control appetite and for anti-obesity treatment. The gene discussed is GHRL; the disease is obesity due to melanocortin 4 receptor deficiency.